Lilly to trial kinase inhibitors with Immunocore's TCR candidate in melanoma

Eli Lilly has signed a second collaboration with Immunocore, this time exploring the use of Immunocore's lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma.